Metraipolis › archive › dc_db91ccbba1c1
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial — Europe PMC PMID:42231943
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42231943
- DOI
- 10.1093/ofid/ofag266
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T17:10:43.814Z
- SHA-256 of the archived text
2523eb8ba31dc16b771a79eb8d6624fa2a74bc124618ec9f86e797094fdc975a- Stable URL of this page
https://metraipolis.com/documento/dc_db91ccbba1c1
How to cite
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial — Europe PMC PMID:42231943 — Europe PMC (en), https://europepmc.org/article/MED/42231943 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db91ccbba1c1 (Metraipolis archive dc_db91ccbba1c1, sha256 2523eb8ba31dc16b771a79eb8d6624fa2a74bc124618ec9f86e797094fdc975a)
BibTeX
@misc{dcdb91ccbba1c1,
title = {Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial — Europe PMC PMID:42231943},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42231943},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db91ccbba1c1; sha256 2523eb8ba31dc16b771a79eb8d6624fa2a74bc124618ec9f86e797094fdc975a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42231943. Agents can read the archived copy with the MCP tool read_document.